EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...

TODAY i have some great news to share. Besides the fact that last week was the King's Birthday, something exciting was happening in the HIV ...

Pre-exposure prophylaxis (PrEP), as an effective means to reduce new HIV infections in high-risk populations, is listed as ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which ...

Amidst limited doses, priority will be given to those at substantial risk of HIV acquisition, such as adolescent girls and young women who are engaged in marital or concurrent sexual partnerships." ...

We may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...

The results suggest the possibility of a vaccine for HIV/AIDS, which killed more than half a million people last year.

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on ...

Healio received an APEX award for a 2024 report on the cloudy future of HIV vaccine research in the age of long-acting ...

Blacks and Hispanics are particularly affected by HIV, making up more than half (70 percent) of estimated new HIV infections ...